Nuclear MAST4 Suppresses FOXO3 through Interaction with AKT3 and Induces Chemoresistance in Pancreatic Ductal Carcinoma
Authors:
- Rina Fujiwara-TaniRFRina Fujiwara-Tani
- Takamitsu SasakiTSTakamitsu Sasaki
- Ujjal Kumar BhawalUjjal Kumar Bhawal
- Shiori MoriSMShiori Mori
- Ruiko OgataRORuiko Ogata
- Rika SasakiRSRika Sasaki
- Ayaka IkemotoAIAyaka Ikemoto
- Shingo KishiSKShingo Kishi
- Kiyomu FujiiKFKiyomu Fujii
- Hitoshi OhmoriHOHitoshi Ohmori
- Masayuki ShoMSMasayuki Sho
- Hiroki KuniyasuHKHiroki Kuniyasu
Open Access
- 5 April 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (7) , 4056
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is highly malignant, with a 5-year survival rate of less than 10%. Furthermore, the acquisition of anticancer drug resistance makes PDAC treatment difficult. We established MIA-GEM cells, a PDAC cell line resistant to gemcitabine (GEM), a first-line anticancer drug, using the human PDAC cell line—MIA-PaCa-2. Microtubule-associated serine/threonine kinase-4 (MAST4) expression was increased in MIA-GEM cells compared with the parent cell line. Through inhibitor screening, dysregulated AKT signaling was identified in MIA-GEM cells with overexpression of AKT3. MAST4 knockdown effectively suppressed AKT3 overexpression, and both MAST4 and AKT3 translocation into the nucleus, phosphorylating forkhead box O3a (FOXO3) in MIA-GEM cells. Modulating FOXO3 target gene expression in these cells inhibited apoptosis while promoting stemness and proliferation. Notably, nuclear MAST4 demonstrated higher expression in GEM-resistant PDAC cases compared with that in the GEM-sensitive cases. Elevated MAST4 expression correlated with a poorer prognosis in PDAC. Consequently, nuclear MAST4 emerges as a potential marker for GEM resistance and poor prognosis, representing a novel therapeutic target for PDAC.Keywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology (19K16564, 20K21659, 23K10481, 22K11396, 21K11223, 22H04922)
- Ministry of Education, Culture, Sports, Science and Technology (19K16564, 20K21659, 23K10481, 22K11396, 21K11223, 22H04922)
This publication has 54 references indexed in Scilit:
- FOXO3 regulates a common genomic program in aging and glioblastoma stem cellsAging and Cancer, 2021
- Pancreatic CancerJAMA, 2021
- Estrogen-Responsive Gene MAST4 Regulates Myeloma Bone DiseaseJournal of Bone and Mineral Research, 2020
- miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3Tumor Biology, 2015
- FOXO3-mediated up-regulation of Bim contributes to rhein-induced cancer cell apoptosisApoptosis, 2014
- The emerging multiple roles of nuclear AktBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2012
- Nuclear translocation of active AKT is required for erythroid differentiation in erythropoietin treated K562 erythroleukemia cellsThe International Journal of Biochemistry & Cell Biology, 2009
- Akt phosphorylation is essential for nuclear translocation and retention in NGF-stimulated PC12 cellsBiochemical and Biophysical Research Communications, 2006
- Expression of receptors for advanced glycation end‐products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancerThe Journal of Pathology, 2001
- Interferon‐alpha prevents selection of doxorubicin‐resistant undifferentiated‐androgen‐insensitive metastatic human prostate cancer cellsThe Prostate, 2001